skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

China overhauls regulatory bodies

 

 

China's State Council has proposed a new reorganization plan that will reduce the number of state agencies overseeing drug regulation, in a new proposal calling for the merger of three agencies including the China FDA (CFDA).

Per the proposal, the CFDA will be merged with its regulation enforcement agency, the State Administration for Industry and Commerce Administration (SAIC), and its inspection agency, the State Administration for Quality, Safety Inspection and Quarantine (AQSIQ) to become a new agency, the National Regulatory and Management Commission.

Under the new agency, the CFDA will become the China Drug Administration (CDA), splitting off its foods regulatory function to other agencies.

"Given the special characteristics of drug products regulatory work, the China Drug Administration is split from food but under the National Market Regulatory and Management Administration," noted the announcement. (All official English names of the new bodies have yet to be confirmed.) 

"Drugs will be regulated at the provincial and state level, drug sales and commercial activities will be administrated by municipal and county-level regulatory authorities," it added.

"The responsibilities [of the new combined agency] include: overseeing regulatory management; registering products and makers and publicizing and sharing information; organizing enforcement activities; taking charge of anti-trust enforcement; regulating and maintaining market order; and being responsible for quality and safety," noted a March 13 announcement. "The China Food and Drug Administration will not be kept as it is."

The State Council is seeking approval for the proposals from the ongoing China's National People's Congress, being held in Beijing from March 5-18.

New Medical Reimbursement Agency

If realized, the plans also include the formation of a new Medical Reimbursement Agency (MRA) that will be the first and most influential agency directly under the State Council to oversee medical insurance policy-making in China.

Currently, there are three basic health insurance schemes to cover urban employees, township residents, and rural residents, which are managed separately by the Ministry of Human Resources and Social Security  (MHRSS), and the National Health and Family Planning Commission (NHFPC). Upon the birth of the new agency, the three schemes will be consolidated into a single agency.

The new MRA will also take over drug price regulation, and health service pricing and reimbursement policy-making, from the National Reform and Development Commission (NRDC), and will also oversee centralized procurement for drugs and medical devices.

"The main responsibilities include: making and enforcing policies for medical insurance, childbirth and child support as well as medical aid; improving the cross-regional health insurance reimbursement payment system; making policies and adjusting prices for drugs and health services; and setting policies for drug bidding and consumable procurement," an official statement said.

Strengthening Oversight

Since April 2013, when the CFDA was created after the then State Food and Drug Administration gained independence and separated from the then Ministry of Health, the agency has seen several changes, but nothing comparable to the new proposals in terms of scale.

Analysts say the moves are a step to enhance enforcement and strengthen oversight via a split of functions. "It is potentially a separation of pre-market and post-market functions into two agencies," said Katherine Wang, partner at law firm Rope & Gray's Shanghai office. "The potential impact to the industry could be different standards in enforcing the regulations," added the legal expert.

One of the agencies CFDA is to be merged with is SAIC, which is the main regulatory enforcer in China.The old CFDA has traditionally not been an enforcement agency, as it has not had the tools and manpower to perform this function. After the merger, the regulation of products' post-market commercial activities is expected to be enforced by the former SAIC component under the new umbrella body.

 SAIC in 2013 shocked the industry by waging a nationwide crackdown on multiple multinational drug makers, and sent companies including GSK to prosecution.

NHFPC To Go

Meanwhile, China's National Health and Family Planning Commission, formerly the ministry of Health, will also undergo changes. It will be merged into the National Health Commission, a newly created agency tasked with overseeing health policy-making, deepening healthcare reforms, and essential drugs, as well as public health crises, aging and habitation.

Some see this plan as a sign of China switching from treating diseases towards disease management and preventative health.

From the editors of PharmAsia News.

 

Read also

  • In Vivo: strategic insights for life sciences decision-maker...

    Pharma News and Healthcare Business Insights

    <p><span>Pharma Intelligence offers a wealth of pharmaceutical industry news and strategic insight into the healthcare &amp; biotechnology markets from around the world. Working in an interconnected global network, our 65 journalists and over 300 in-house analysts supply comprehensive analysis and reports.</span></p>

  • Pink Sheet: global policy and regulatory coverage

    Cancer Immunotherapy: When To Stop Treatment Remains Unanswered Question

    02 Aug 2017

    Long-term or open-ended treatment with PD-1/PD-L1 inhibitors is a burden for patients and the healthcare system and does not fit the biological paradigm of cancer immunotherapies, experts say; however, challenges to studying shorter durations include fears of undertreatment and patient objections to stopping a therapy that appears to be working.

    Topics Clinical trials

  • Biomedtracker: follow the drug development process

    Accurate, Intuitive and Updated In Real Time

    03 Apr 2017

    Learn why pharmaceutical, biotech, and investment companies rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.

;

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: